The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.
Pronunciation: des-IP-ra-meen HYE-droe-KLOR-ide
Class: Tricyclic compound
- Tablets 10 mg
- Tablets 25 mg
- Tablets 50 mg
- Tablets 75 mg
- Tablets 100 mg
- Tablets 150 mg
Inhibits reuptake of norepinephrine and serotonin in CNS.
Metabolized in the liver.
Approximately 70% excreted in the urine.
2 to 5 days.
2 to 3 wk.
Special PopulationsRenal Function Impairment
No data available.Hepatic Function Impairment
No data available.Elderly
Rate of metabolism is slower. Dosage adjustment is recommended.Smokers
Tobacco smoke can induce liver enzyme activity, thereby reducing desipramine plasma levels.
Indications and Usage
For the treatment of depression.
Alcohol dependence and major secondary depression, alcoholism, anxiety, attention deficit hyperactivity disorder (ADHD), bulimia nervosa, enuresis, diabetic neuropathy, postherpetic neuralgia, Tourette syndrome with comorbid ADHD, traumatic brain injury.
Hypersensitivity to desipramine; in combination with or within 14 days of treatment with an MAOI; during acute recovery phases of MI.
Dosage and AdministrationAdults
PO 100 to 200 mg/day (max, 300 mg/day).Elderly and Adolescent Patients
PO 25 to 100 mg/day (max, 150 mg/day).
- Initiate therapy at a low dose level and increase the dose according to tolerance and clinical response.
- Lower dosages are recommended for outpatients compared with hospitalized patients, who are closely supervised.
- Initial therapy may be given in divided doses or as a single daily dose.
- Maintenance therapy may be given on a once-daily schedule for convenience and compliance.
- If serious adverse reactions occur, reduce dosage or alter treatment.
- Following remission, maintenance medication may be required for a period of time and should be given at the lowest dose that will maintain remission.
Store between 59° and 86°F, preferably below 86°F. Protect from excessive heat.
Alcohol may induce liver enzyme activity, thereby reducing desipramine levels. Response to alcohol may be exaggerated with coadministration. Caution patients that mental and physical abilities required for hazardous tasks may be impaired.Anticholinergics (eg, diphenhydramine, scopolamine)
Anticholinergic effects may be enhanced. Closely monitor clinical response and adjust treatment as needed.Bupropion, mibefradil
Desipramine plasma concentrations may be elevated, increasing the pharmacologic effects and the risk of adverse reactions. Monitor plasma concentrations and for signs and symptoms of adverse reactions. Adjust the desipramine dose as needed.Carbamazepine
Serum carbamazepine levels may be elevated, while desipramine levels may be decreased. Monitor plasma levels of both drugs and the clinical response when concurrent use of either drug is started or stopped. Adjust treatment as needed.Cholestyramine
Cholestyramine may reduce the GI absorption of desipramine, decreasing the pharmacologic effect. Separate the administration times by as much as possible. However, separating the administration times by 6 h may still interfere with desipramine absorption. Monitor the clinical response. If an interaction is suspected, be prepared to increase the desipramine dose as needed.Cisapride
Cisapride is contraindicated in patients receiving desipramine because of the increased risk of life-threatening cardiac arrhythmias resulting from prolongation of the QT interval.Clonidine
May result in hypertensive crisis. Avoid coadministration.CNS depressants
CNS and respiratory effects may be increased. Coadminister with caution. Warn patients that mental and physical abilities required for hazardous tasks may be impaired.Disulfiram
Pharmacologic effects of desipramine may be increased. Concurrent use may also be associated with a high frequency of acute organic brain syndrome. Monitor the clinical response. If an interaction is suspected, stop or decrease the dosage of desipramine.Drugs that inhibit CYP2D6 (eg, cimetidine, cinacalcet, duloxetine, flecainide, phenothiazines, propafenone, protease inhibitors [eg, ritonavir], quinidine, terbinafine, venlafaxine)
Desipramine plasma levels may be elevated, increasing the pharmacologic effects and adverse reactions. Monitor desipramine plasma levels. Dosage reduction of desipramine may be necessary.Fluconazole
Desipramine plasma concentrations and risk of adverse reactions may be increased. Monitor desipramine plasma concentrations and the clinical response when starting or stopping fluconazole. Adjust the desipramine dose as needed.Food
A high-fiber diet may decrease desipramine absorption, decreasing its therapeutic effects. Observe the patient's response to desipramine during ingestion of a high-fiber diet. Adjust the diet as needed.Gatifloxacin, levofloxacin, moxifloxacin
Avoid concurrent use with levofloxacin. Administer desipramine with gatifloxacin or moxifloxacin with caution. The risk of life-threatening cardiac arrhythmias may be increased.Guanethidine, guanfacine
The hypotensive action of these agents may be inhibited. If coadministration cannot be avoided, monitor BP and adjust the dose of these agents as needed.Iobenguane
Desipramine may reduce uptake and diagnostic efficacy of iobenguane. False-negative iobenguane imaging tests may result. It is recommended that desipramine be discontinued for at least 5 biological half-lives (approximately 48 h) prior to iobenguane administration.Lithium
The risk of adverse reactions (eg, neurotoxicity, psychotic symptoms) may be increased. Monitor the clinical response. If an interaction is suspected, it may be necessary to discontinue one of the agents and adjust treatment as needed.MAOIs (eg, phenelzine)
Hyperpyretic crises, severe convulsions, and death may occur if desipramine is administered together or within 14 days of MAOI treatment.Psychotropic agents (eg, hypnotics, sedatives, tranquilizers)
Coadministration may enhance the sedative effects of both drugs. Use with caution. Warn patients that mental and physical abilities required for hazardous tasks may be impaired.Rasagiline, tramadol
May act synergistically to precipitate serotonin syndrome. Closely monitor the clinical response. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.SSRIs (eg, fluoxetine, paroxetine, sertraline)
The pharmacologic and toxic effects of desipramine may be increased. Serotonin syndrome has been reported. Dosage reduction may be necessary. Allow sufficient time before initiating desipramine in a patient being withdrawn from fluoxetine because of fluoxetine's long half-life (ie, at least 5 wk may be necessary).Sympathomimetics (eg, epinephrine)
The pressor response to direct- and indirect-acting sympathomimetics may be increased or decreased, respectively. Dosage adjustment of the sympathomimetic may be necessary. Closely monitor for dysrhythmias and hypertension.Thyroid hormones (eg, levothyroxine)
The risk of CV toxicity, including arrhythmias, may be increased. Use with extreme caution and closely monitor cardiac function.Valproic acid
Desipramine plasma levels may be elevated, increasing the pharmacologic effects and adverse reactions. Monitor plasma desipramine concentrations and adjust the dose as needed.
Arrhythmias, heart block, hypertension, hypotension, MI, palpitations, PVCs, stroke, tachycardia, ventricular fibrillation, ventricular tachycardia.
Alterations in EEG patterns; anxiety; ataxia; confusional states with hallucinations, delusions, disorientation, agitation, and restlessness; dizziness; drowsiness; exacerbation of psychosis; extrapyramidal symptoms; fatigue; headache; hypomania; incoordination; insomnia; nightmares; NMS symptoms; numbness; paresthesias of extremities; peripheral nephropathy; seizures; tingling; tremors; weakness.
Blurred vision, disturbances in accommodation, increased IOP, mydriasis, tinnitus.
Abdominal cramps, anorexia, black tongue, constipation, diarrhea, dry mouth rarely associated with sublingual adenitis, epigastric distress, nausea, paralytic ileus, peculiar taste, stomatitis, vomiting.
Breast enlargement and galactorrhea in women, decreased or increased libido, delayed micturition, dilation of the urinary tract, gynecomastia in men, impotence, nocturia, painful ejaculation, testicular swelling, urinary frequency, urinary retention.
Bone marrow depression, including agranulocytosis; eosinophilia; purpura; thrombocytopenia.
Altered hepatic function, elevated alkaline phosphatase, elevated LFTs, hepatitis, increased pancreatic enzymes, jaundice.
Cross-sensitivity with other tricyclic drugs, drug fever, edema (general or of the face and tongue), itching, petechiae, photosensitization, skin rash, urticaria.
Elevation or depression of blood glucose levels, SIADH, weight gain or loss.
Acute collapse; fever; flushing; parotid swelling; proneness to falling; sudden death; withdrawal symptoms, including headache, malaise, and nausea.
Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders compared with placebo. Anyone considering the use of desipramine or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Closely observe and appropriately monitor patients of all ages who are started on antidepressant therapy for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication with the prescribing health care provider. Desipramine is not approved for use in children.
Prior to initiating treatment, adequately screen patients with depressive symptoms to determine if they are at risk for bipolar disorder. Closely observe and appropriately monitor all patients being treated with antidepressants for any indication for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy or at times of dose changes (increases or decreases). Perform leukocytes and differential counts in any patient who develops fever and sore throat during therapy; discontinue the drug if there is evidence of pathologic neutrophil depression.
Category C .
Excreted in breast milk.
Safety and efficacy not established. Sudden death has been reported in children taking desipramine.
Use with caution because of the greater incidence of renal impairment in elderly patients; lower dosages are recommended.
The risk of toxic reactions to this drug may be greater in patients with impaired renal function.
Special Risk Patients
Use drug with caution in patients with history of seizures, urinary retention, and glaucoma, and in patients with thyroid disease or patients receiving thyroid medication.
May impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.
Not approved for treating bipolar depression.
Use extreme caution in CV disorder because of the possibility of conduction defects, arrhythmias, tachycardias, strokes, and MI; also use with extreme caution in patients who have a family history of sudden death, cardiac dysrhythmias, or cardiac conduction disturbances.
Because of CV effects, discontinue desipramine as soon as possible prior to elective surgery.
Both increased and decreased blood sugar levels may occur.
Therapy in patients with manic-depressive illness may induce a hypomanic state after the depressive phase terminates.
Psychosis may be exacerbated.
Agitation, cardiac arrhythmias, CNS depression, coma, confusion, dilated pupils, disturbed concentration, drowsiness, ECG changes, hyperactive reflexes, hyperpyrexia, hypothermia, muscle rigidity, seizures, severe hypotension, stupor, transient visual hallucinations, vomiting.
- Inform patients, families, and caregivers about the benefits and risks associated with desipramine treatment; counsel them in its appropriate use. Instruct patients, families, and caregivers to read the Medication Guide and assist them in understanding its contents. Give patients the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have.
- Encourage patients, families, and caregivers to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is increased or decreased. Advise families and caregivers to watch for the emergence of such symptoms on a day-to-day basis because changes may be abrupt. Report such symptoms to the patient's health care provider, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and may indicate a need for very close monitoring and, possibly, changes in the medication.
- Warn patients that while taking this drug their response to alcoholic beverages may be exaggerated.
- Caution the patient that this drug may impair the mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.
- Advise patients undergoing elective surgery to discontinue desipramine as soon as possible prior to surgery date.
- Advise patient that medication may cause photosensitization and to avoid unnecessary exposure to sunlight or tanning lamps, and to use sunscreens and wear protective clothing to avoid photosensitivity reactions.
- Advise patients with diabetes that desipramine may raise or lower blood glucose.
Copyright © 2009 Wolters Kluwer Health.